Borderline Findings in<i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice

One of the most common clinical indications for amino acid PET using the tracer <i>O</i>-(2-[<sup>18</sup>F]-fluoroethyl)-l-tyrosine (<sup>18</sup>F-FET) is the differentiation of tumor relapse from treatment-related changes in patients with gliomas. A subset of patients may present with an uptake of <sup>18</sup>F-FET close to recommended threshold values. The goal of this study was to investigate the frequency of borderline cases and the role of quantitative <sup>18</sup>F-FET PET parameters in this situation. <b>Methods:</b> We retrospectively identified 439 patients with pretreated gliomas who underwent <sup>18</sup>F-FET PET for suspected tumor relapse and in whom the final diagnoses were confirmed by histopathology (<i>n</i> = 175) or clinical course (<i>n</i> = 264). Two experienced nuclear medicine physicians, masked to the final diagnoses, evaluated visually the PET scans by consensus. The findings were classified into 3 categories: clearly positive findings, borderline findings, or clearly negative findings. The diagnostic performance of established <sup>18</sup>F-FET PET parameters (i.e., tumor-to-brain ratio [TBR], time-to-peak ratio, slope, intercept) was evaluated separately for these 3 groups using receiver operating characteristics analyses. <b>Results:</b> In the visual analysis, <sup>18</sup>F-FET uptake was classified as clearly negative in 67 patients (15%), clearly positive in 234 patients (53%), and borderline in 136 patients (31%), with averaged mean TBR values of 1.5, 2.3, and 1.9, respectively. Receiver operating characteristics analysis showed a high accuracy for TBR values in patients rated as clearly positive or negative in visual rating (area under curve [AUC], 0.84-0.86), whereas the diagnostic performance of TBR values in borderline cases according to visual analysis was significantly lower (AUC, <0.60). Using TBR values ± 10% above or below the cutoff values increased the AUC by approximately 10% (AUC, 0.82-0.84). <b>Conclusion:</b> A considerable number of patients may present with borderline findings in <sup>18</sup>F-FET PET. In these patients, quantitative parameters should be used with caution for decision-making. The use of TBR values above or below the range of the cutoff values ±10% may increase the reliability of quantitative parameters to differentiate between tumor relapse and treatment-related changes.

Authors

Institutions

Publication Details

Journal
Journal of Nuclear Medicine
Published
2025-01-16
DOI
https://doi.org/10.2967/jnumed.124.268768
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Borderline Findings inO-(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice

Martin Köcher, Michael Wollring, Felix M. Mottaghy, Michael Stoffel et al.
Journal of Nuclear Medicine
Glioma Diagnosis and Treatment
article

Borderline Findings inO-(2-[18F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice

Martin Köcher, Michael Wollring, Felix M. Mottaghy, Michael Stoffel, Marion Rapp, Garry Ceccon, Norbert Galldiks, Christoph Lerche, Karl‐Josef Langen, Jurij Rosen, Christian Filß, Gabriele Stoffels, Jan‐Michael Werner, N. Jon Shah, Elke Hattingen, Joachim P. Steinbach, Hans Clusmann, Michael Sabel, Philipp Lohmann, Martin R. Weinzierl, Hosai Noltemeier
article en

Abstract

One of the most common clinical indications for amino acid PET using the tracer <i>O</i>-(2-[<sup>18</sup>F]-fluoroethyl)-l-tyrosine (<sup>18</sup>F-FET) is the differentiation of tumor relapse from treatment-related changes in patients with gliomas. A subset of patients may present with an uptake of <sup>18</sup>F-FET close to recommended threshold values. The goal of this study was to investigate the frequency of borderline cases and the role of quantitative <sup>18</sup>F-FET PET parameters in this situation. <b>Methods:</b> We retrospectively identified 439 patients with pretreated gliomas who underwent <sup>18</sup>F-FET PET for suspected tumor relapse and in whom the final diagnoses were confirmed by histopathology (<i>n</i> = 175) or clinical course (<i>n</i> = 264). Two experienced nuclear medicine physicians, masked to the final diagnoses, evaluated visually the PET scans by consensus. The findings were classified into 3 categories: clearly positive findings, borderline findings, or clearly negative findings. The diagnostic performance of established <sup>18</sup>F-FET PET parameters (i.e., tumor-to-brain ratio [TBR], time-to-peak ratio, slope, intercept) was evaluated separately for these 3 groups using receiver operating characteristics analyses. <b>Results:</b> In the visual analysis, <sup>18</sup>F-FET uptake was classified as clearly negative in 67 patients (15%), clearly positive in 234 patients (53%), and borderline in 136 patients (31%), with averaged mean TBR values of 1.5, 2.3, and 1.9, respectively. Receiver operating characteristics analysis showed a high accuracy for TBR values in patients rated as clearly positive or negative in visual rating (area under curve [AUC], 0.84-0.86), whereas the diagnostic performance of TBR values in borderline cases according to visual analysis was significantly lower (AUC, <0.60). Using TBR values ± 10% above or below the cutoff values increased the AUC by approximately 10% (AUC, 0.82-0.84). <b>Conclusion:</b> A considerable number of patients may present with borderline findings in <sup>18</sup>F-FET PET. In these patients, quantitative parameters should be used with caution for decision-making. The use of TBR values above or below the range of the cutoff values ±10% may increase the reliability of quantitative parameters to differentiate between tumor relapse and treatment-related changes.

Journal of Nuclear MedicineVol. 66(2)
Goethe University Frankfurt (DE), Forschungszentrum Jülich (DE), Maastricht University (NL), Helios Klinikum Krefeld (DE), University Hospital Frankfurt (DE), Jülich Aachen Research Alliance (DE), University Hospital Cologne (DE), Frankfurt Cancer Institute (DE), Heinrich Heine University Düsseldorf (DE), RWTH Aachen University (DE)
Good health and well-being
Openalex Percentile: Top 99%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.